Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Where are we going with SSRIs?

M Isaac1

  • 1Psychopharmacology Evaluation Unit, University Hospital, Lewisham, London, UK. misaac@stekel.demon.co.uk

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|October 16, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of amino acid sequence in a peptidic Cu<sup>+</sup>-responsive luminescent probe inspired by the copper chaperone CusF.

Organic & biomolecular chemistry·2018
Same author

Editorial: Collaborative Efforts to Prevent Alzheimer's Disease.

The journal of nutrition, health & aging·2017
Same author

EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.

The journal of prevention of Alzheimer's disease·2017
Same author

Mental Hospitals in India in the 21st century: transformation and relevance.

Epidemiology and psychiatric sciences·2016
Same author

Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.

Eye (London, England)·2016
Same author

Using a commercial software package to support treatment planning peer review activities in small radiotherapy departments.

The British journal of radiology·2015
Same journal

Commentary on: The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Corrigendum to "Functioning assessment short test for autism (FAST-A): a tool to evaluate adaptive functioning in autistic adults" [European Neuropsychopharmacology, 112, 112887].

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Genomic relationship between polyendocrine metabolic ovarian syndrome and bipolar disorder.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Genetic overlap between depression and C-reactive protein levels: Evidence from a cross-trait analysis.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Variability in AI-generated psychedelic definitions across major chatbots.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

In-patient treatment and structural dysconnectivity in major depression - A longitudinal connectome study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
See all related articles

Selective serotonin reuptake inhibitors (SSRIs) remain a primary treatment for depression. This review explores their ongoing role, including use in physical illnesses and new therapeutic areas like anxiety disorders.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Selective serotonin reuptuptake inhibitors (SSRIs) are a leading treatment for depression.
  • Newer antidepressants necessitate a re-evaluation of SSRIs' role.

Purpose of the Study:

  • To review the current and future applications of SSRIs in managing depression.
  • To assess SSRIs' efficacy in specific patient populations and emerging therapeutic areas.

Main Methods:

  • Literature review of studies on SSRIs in depression and related disorders.
  • Analysis of efficacy data, including augmentation strategies and use in comorbid physical illnesses.

Main Results:

  • SSRIs continue to be first-line for depression, with potential for faster onset via pindolol augmentation.

Related Experiment Videos

  • Evidence supports SSRI use in patients with physical illnesses like ischemic heart disease.
  • SSRIs demonstrate efficacy in panic disorder, OCD, social anxiety disorder, and emerging areas like PTSD and GAD.

    • Conclusions:

    • SSRIs maintain a crucial position in depression management.
    • Their application is expanding to include complex patient groups and new psychiatric indications.